Law Debenture investment trust increases AstraZeneca and GSK holdings | October factsheet
Law Debenture Corporation's NAV fell 0.6% in October, underperforming the FTSE All-Share. The trust increased holdings in AstraZeneca and GSK, while selling Roche and Becton Dickinson. Defensive sectors outperformed, with Shell, BP, Relx, and LSEG rising, while industrials like Hill & Smith declined.
How this was made

The 30-second read
Why it matters
The disclosed fund trades provide fresh insight into short‑term demand for specific healthcare stocks, offering modest trading signals.
Market read
Fund rebalancing creates limited but actionable signals for the four affected stocks.
What to watch
Potential tax‑loss harvesting or liquidity needs could be driving the sales of Roche and BDX rather than fundamental concerns.
Background
Law Debenture Corporation plc released its October 2026 factsheet, detailing portfolio performance and recent trades.
Ticker impact
Law Debenture fund added to its AstraZeneca holding after an initial purchase last month.
likely slight buying pressure from fund accumulation
Fund disclosed a new purchase, indicating fresh demand.
Law Debenture fund rotated proceeds into GSK, citing an overreaction to its recent results.
likely mild buying pressure as fund adds to position
New allocation suggests confidence in near‑term performance.
Law Debenture fund sold its position in Swiss pharmaceutical Roche.
likely modest selling pressure as fund exits
Disposal of shares signals reduced exposure.
Law Debenture fund sold its position in US medical‑devices company Becton Dickinson.
likely modest selling pressure as fund reduces holding
Fund exit may weigh on short‑term sentiment.
Market effects
Increased fund exposure to healthcare may slightly boost sector sentiment, while exits from Roche and BDX could dampen related sub‑segments.
UK‑listed AstraZeneca and UK‑based GSK gains reflect modest UK market support; US‑listed BDX impact is limited.
Fund rebalancing is a niche driver, unlikely to affect broader market trends.
Counterpoint
The fund's modest purchases may be outweighed by broader market weakness in healthcare, limiting upside.
Key entities
- FundLaw Debenture Corporation plc
UK investment trust managing a diversified portfolio.


